Lascco
Business Services · Switzerland · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Route De La Corniche 8, Epalinges, Vaud,...Website
www.lascco.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Lascco
LASCCO SA has developed the PSP diagnostic test, which identifies individuals at high risk of developing sepsis, a critical public health issue. The PSP test, licensed to Abionic SA, has received FDA 510(k) clearance and EU IVDR certification, and is being introduced in China through a partnership with Fapon. This innovative test provides rapid results from a small blood sample, enhancing patient triage and timely treatment for sepsis. With over 80 peer-reviewed publications supporting its efficacy, LASCCO aims to improve sepsis detection and management in healthcare settings.Explore more
Lascco Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lascco your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Lascco has recently received funding, and reach out quickly before it becomes old news!
Check out if Lascco is spiking on competitors!
Funding: Get notified immidiatlly once Lascco has new funding data
Congratulate Masked Content for being promoted to Masked Content at Lascco
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Lascco launches new products
Click to see if Lascco had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Lascco recently announced quarterly report
Lascco, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Lascco
Find 2 more new buyers
Company Profile Activity
Activity Insights
Lascco is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Lascco is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Lascco.
Lascco Tech Stack
A closer look at the technologies used by Lascco
Lascco News & Media
Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has entered into a worldwide licensing agreement with Combioxin SA (“Combioxin”), a clinical-stage biotechnology company based in Epalinges, Switzerland, for the commercial rights to CAL02, a novel first-in-class antitoxin agent ready for Phase 2b/3 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs. Under the Agr
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Lascco
Sign Up For FreeTo access detailed company insights
LASCCO SA has developed the PSP diagnostic test, which identifies individuals at high risk of developing sepsis, a critical public health issue. The PSP test, licensed to Abionic SA, has received FDA 510(k) clearance and EU IVDR certification, and is being introduced in China through a partnership with Fapon. This innovative test provides rapid res... Read More
